Faculty Information   
   日本語 >>
  1. TOP page
    2. >
  2. Clinical Medicine Seminars

Journal
Presentation
    （Last updated : 2021-12-03 10:23:56）
  Miyoshi Yasuo
   Department   Specialty Division  , Clinical Medicine Seminars
   Position  
■ Journal
1. Introduction　 Basal-like subtype and BRCA1 dysfunction in breast cancers. 2008/10
2. Introduction　 Prediction of hormone sensitivity for breast cancers 2010/04
3. Original article　 Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis 2013/02
4. Original article　 Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. 2013/02
5. Original article　 Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. 2013/12
6. Original article　 Development of an integrated support system for hereditary cancer and its impact on gynecologic services. 2013/12
7. Original article　 Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. 2014/01
8. Original article　 Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancer. 2014/06
9. Original article　 Phase 2 Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer. 2014/07
10. Original article　 Strategy for treatment of isolated contralateral supraclavicular recurrence in patient with breast cancer after sentinel lymph node biopsy without axillary lymph node dissection. 2014/07
11. Original article　 Spontaneous regression of primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) colliding with invasive ductal carcinoma of thebreast: a case report. 2014/09
12. Original article　 Development of an integrated support system for hereditary cancer and its impact on gynecologic services. 2014/12 Link
13. Original article　 Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. 2014/12
14. Original article　 Association between 18F-FDG uptake and molecular subtype of breast cancer. 2015/05
15. Original article　 Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011 2015/05
16. Original article　 Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. 2015/05
17. Original article　 Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2- Breast Cancer. 2015/06
18. Original article　 High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. 2015/06
19. Original article　 Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. 2015/07
20. Original article　 C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. 2015/07
21. Original article　 C4.4A and Aldehyde Dehydrogenase1(ALDH1)May Contribute to breast Cancer not Mediated Through epithelial-Mesenchymal Transition. 2015/11
22. Original article　 High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. 2015/12
23. Original article　 Present and future role of FDG-PET/CT imaging in the management of breast cancer 2016/01
24. Original article　 Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer 2016/03
25. Original article　 Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. 2016/03
26. Original article　 Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. 2016/04
27. Original article　 Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. 2016/04
28. Original article　 Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. 2018/02
29. Other　 Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0. 2018/05
Display 5 items
Display all(29)
■ Presentation
1. Nuclear-19S proteasome associated gene 1 contributes to the aggressiveness of triple negative breast cancer cells  2013/10/04
2. Genetic counseling for female patients with hereditary cancer symdromes  2013/10/05
3. Chemotherapy, but not body mass index has impact on joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.  2013/12
4. Activation of PI3K/Akr/mTOR pathway but not of MARK pathway may be associated with luminal B subtype irrespective of menopausal status.  2013/12/13
5. Effect of body mass index and menopausal disorders during menopause on vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes.  2014/06/01
6. Personalized medicine of breast cancer based on molecular diagnoses.  2014/07/19
7. Factors influencing on discontinuation of adjuvant anastrozole in postmenopausal Japanese breast cancer patients: Results from a prospective multicenter cohort study of patient-reported outcomes.  2014/12/10
8. Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation.  2014/12/12
9. Class I HDAC inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.  2015/05/29
10. High Levels of serumC-terminal crosslinking telopeptide of type 1 collagen at baseline are associated with poor prognosis for breast cancer patients.  2015/12/10
11. Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation  2015/12/10
12. Differences in patterns of change of bone turnover markers during treatment with bone-modifying agents of breast cancer patients with bone metastases  2015/12/12
13. Gremlin2 is repressed in invasive endometrial cancer and inhibits cell growth in vitro  2016/04/16
14. Participants in a randomized-controlled trial (SELECT BC) had longer overall survival than non-participants: a prospective cohort study.  2016/06/03
15. Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy.  2016/12/08
Display 5 items
Display all(15)
mail